Newly developed anti-angiogenic therapy in non-small cell lung cancer

Jingjing Qu, Yongchang Zhang, Xue Chen, Haiyan Yang, Chunhua Zhou and Nong Yang _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:10147-10163. https://doi.org/10.18632/oncotarget.23755

Metrics: PDF 2378 views  |   HTML 2934 views  |   ?  


Jingjing Qu1, Yongchang Zhang1, Xue Chen1, Haiyan Yang1, Chunhua Zhou1 and Nong Yang1

1Department of Lung Cancer and Gastrointestinal Oncology Medicine, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, 410013, China

Correspondence to:

Nong Yang, email: [email protected]

Keywords: angiogenesis; combined with chemotherapy; tyrosine kinase inhibitor; immunotherapy; NSCLC

Received: August 13, 2017     Accepted: November 16, 2017     Published: December 26, 2017


Angiogenesis and its role in the growth and development of non-small cell lung cancer (NSCLC) metastases has become an increasing clinical problem. Vascular endothelial growth factor (VEGF) plays a key role in advanced NSCLC. To some extent, anti-angiogenic therapies acquired some efficacy in combination with chemotherapy, target therapy and immunotherapy. However, the reliable clinical benefit obtained with these drugs is still questionable and often quantitatively limited. In this review, the authors highlight the data obtained from first-line, second-line, epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) target therapy and immunotherapy in NSCLC patients who are treated with anti-angiogenic molecules in advanced NSCLC. The purpose of this study is to help us truly understand how to best use angiogenesis therapy in advanced NSCLC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23755